

Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity (B3)

Scientific Organizers: Daniel J. Cua, E. John Wherry and Carla V. Rothlin

February 18–22, 2019

Beaver Run Resort, Breckenridge, Colorado, USA

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Organized in collaboration with Cancer Research UK

Sponsored by AbbVie Inc., BioLegend, Inc., EMD Serono Research and Development Institute, Inc., Genentech, Inc., Incyte Corporation, MacroGenics, Inc., Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., MorphoSys AG, Pfizer Inc., Roche, Surface Oncology and Takeda Pharmaceutical Company Limited

IT'S NOT TOO LATE TO SUBMIT YOUR ABSTRACT. Abstracts received can no longer be considered for oral short talks. Abstracts for poster display opportunities will be accepted until 6 weeks before meeting start date midnight MST.

BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. [Click here for more details.](#)

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our [policies](#).

DEADLINES:

**All deadlines end at 11:59 PM US Mountain Standard Time*

Scholarship Deadline: Oct 23, 2018 [\[details\]](#)

Discounted Abstract Deadline: Oct 23, 2018 [\[details\]](#)

Abstract Deadline: Nov 15, 2018 [\[details\]](#)

Discounted Registration Deadline: Dec 18, 2018 [\[details\]](#)

[Click here to view Cancellation Policy](#)

No registration fees are used to fund entertainment or alcohol at this conference

Conference Program [Print](#) | [View meeting in 12 hr \(am/pm\) time](#)

The meeting will begin on Monday, February 18 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Friday, February 22 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Saturday, February 23 in order to fully experience the meeting.

MONDAY, FEBRUARY 18

16:00–20:00	Arrival and Registration	Colorado Ballroom Foyer
18:00–20:00	Welcome Mixer No registration fees are used to fund alcohol served at this function.	Colorado Ballroom Foyer

TUESDAY, FEBRUARY 19

07:00–08:00	Breakfast	Summit Gallery
08:00–09:00	Welcome and Keynote Address Registered attendees can view abstracts starting on 01/18/2019 Arlene H. Sharpe , Harvard Medical School, USA <i>Checkpoint Blockade for Cancer Immunotherapy</i>	Colorado Ballroom
09:00–11:15	Checkpoint Blockade Predisposes Patients to Autoimmunity	Colorado Ballroom

[Registered attendees](#) can view abstracts starting on 01/18/2019

Jeffrey A. Bluestone, University of California, San Francisco, USA
Development of Syngeneic NOD Tumor Models to Study Tumor Immunity in Autoimmune-Prone Mice

Coffee Break

Jennifer Ann Wargo, University of Texas MD Anderson Cancer Center, USA
Immune Mechanisms Influencing Checkpoint Therapy

Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA
Regulation of Autoimmunity and Cancer by PD-1 and LAG3

Short Talk(s) Chosen from Abstracts

11:15–17:00

On Own for Lunch

11:15–13:00

Poster Setup

[Breckenridge Ballroom](#)

13:00–22:00

Poster Viewing

[Breckenridge Ballroom](#)

16:30–17:00

Coffee Available

[Colorado Ballroom](#)
[Foyer](#)

17:00–19:00

Genetics of Autoimmunity and Cancer: What are the Common Denominators?

[Colorado Ballroom](#)

[Registered attendees](#) can view abstracts starting on 01/18/2019

Alex Marson, University of California, San Francisco, USA
Decoding T Cell Circuitry

Elissa K. Deenick, Garvan Institute of Medical Research, Australia
Talk Title to be Announced

Wenjun Ouyang, Amgen, Inc., USA
Lessons from Human Genetics for Autoimmunity and Cancer Therapy

Short Talk(s) Chosen from Abstracts

19:00–20:00

Social Hour with Lite Bites

[Breckenridge Ballroom](#)

No registration fees are used to fund alcohol served at this function.

19:30–22:00

Poster Session 1

[Breckenridge Ballroom](#)

WEDNESDAY, FEBRUARY 20

07:00–08:00

Breakfast

[Summit Gallery](#)

08:00–11:00

Cellular Reprogramming: Regulatory vs. Functional Fate

[Colorado Ballroom](#)

[Registered attendees](#) can view abstracts starting on 01/18/2019

Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Treg Stability in Disease

Mark S. Anderson, University of California, San Francisco, USA
Modulating Self-Tolerance in Autoimmunity and Cancer

Coffee Break

Maria Grazia Roncarolo, Stanford University School of Medicine, USA
T Regulatory Cell-Based Therapy in Cancer and Autoimmunity

Eric Meffre, Yale University School of Medicine, USA
Impaired B Cell Tolerance and Autoimmunity: CTLA-4 Blockade Dirty Secret

Short Talk(s) Chosen from Abstracts

11:00–17:00

On Own for Lunch

11:00–13:00

Poster Setup[Breckenridge Ballroom](#)

13:00–22:00	Poster Viewing	Breckenridge Ballroom
14:30–16:30	Workshop 1: Immune Monitoring of Checkpoint Blockade Therapies	Colorado Ballroom
	Short Talks Chosen from Abstracts	
16:30–17:00	Coffee Available	Colorado Ballroom Foyer
17:00–19:00	Cellular Reprogramming: CD8 T Cell Exhaustion and CD4 T Cell Lineages	Colorado Ballroom
	Registered attendees can view abstracts starting on 01/18/2019	
	E. John Wherry , University of Pennsylvania, USA <i>T Cell Exhaustion and Fate Decisions - Implications for Immunotherapy</i>	
	Andrea Schietinger , Memorial Sloan Kettering Cancer Center, USA <i>Epigenetics of Tumor Immunity</i>	
	W. Nicholas Haining , Dana-Farber Cancer Institute, USA <i>Epigenetic Engineering of Tumor Immunity</i>	
	Short Talk(s) Chosen from Abstracts	
19:00–20:00	Social Hour with Lite Bites	Breckenridge Ballroom
	No registration fees are used to fund alcohol served at this function.	
19:30–22:00	Poster Session 2	Breckenridge Ballroom

THURSDAY, FEBRUARY 21

07:00–08:00	Breakfast	Summit Gallery
08:00–11:00	Macrophage Biology, Tissue Repair, Autoimmunity and Cancer	Colorado Ballroom
	Registered attendees can view abstracts starting on 01/18/2019	
	Mikael J. Pittet , Massachusetts General Hospital, USA <i>Myeloid Cells in Cancer Therapies</i>	
	Carla V. Rothlin , Yale University, USA <i>Coincidence Detectors in Tissue Repair</i>	
	Coffee Break	
	Ming O. Li , Memorial Sloan Kettering Cancer Center, USA <i>Deconstructing the Antigen-Presenting Cell Compartment in Cancer</i>	
	Fiona M. Powrie , University of Oxford, UK <i>Inflammation Driven Cancer: Host and Microbial Pathways</i>	
	Short Talk(s) Chosen from Abstracts	
11:00–17:00	On Own for Lunch	
11:00–13:00	Poster Setup	Breckenridge Ballroom
13:00–22:00	Poster Viewing	Breckenridge Ballroom
16:30–17:00	Coffee Available	Colorado Ballroom Foyer
17:00–19:00	Neutrophils and MDSCs in Host Defense and Cancer	Colorado Ballroom
	Registered attendees can view abstracts starting on 01/18/2019	
	Matthew F. Krummel , University of California, San Francisco, USA <i>Myeloid Cells as Arbiters of Self</i>	
	Catherine Hedrick , La Jolla Institute for Allergy and Immunology, USA <i>Neutrophil Heterogeneity in Cancer</i>	

Susan M. Kaech, The Salk Institute, USA
Nutrient Regulation of Anti-Tumor Immunity

Dmitry I. Gabrilovich, Wistar Institute, USA
Neutrophils and PMN-MDSC in Cancer: Two Sides of Functional Diversity

Short Talk(s) Chosen from Abstracts

19:00–20:00 **Social Hour with Lite Bites** [Breckenridge Ballroom](#)
 No registration fees are used to fund alcohol served at this function.

19:30–22:00 **Poster Session 3** [Breckenridge Ballroom](#)

FRIDAY, FEBRUARY 22

07:00–08:00 **Breakfast** [Summit Gallery](#)

08:00–11:00 **Finding the Cure for Cancer** [Colorado Ballroom](#)

[Registered attendees](#) can view abstracts starting on 01/18/2019

Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Checkpoint Inhibition

Alan J. Korman, Bristol-Myers Squibb, USA
Immune Checkpoint Blockade and Adverse Events in Mice, Cynos and Man

Coffee Break

Emmett V. Schmidt, Merck Research Labs, USA
Drivers in the Clinical Development of Cancer Combination Therapy - Pembrolizumab Combination Therapies, Emerging Results

Robert L. Coffman, Dynavax Technologies, USA
Talk Title to be Announced

Short Talk(s) Chosen from Abstracts

11:00–17:00 **On Own for Lunch**

16:30–17:00 **Coffee Available** [Colorado Ballroom](#)
[Foyer](#)

17:00–18:45 **Integrated Themes across Preclinical and Clinical Treatment of Cancer and Autoimmunity** [Colorado Ballroom](#)

[Registered attendees](#) can view abstracts starting on 01/18/2019

Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
What we can Learn from Combination Immunotherapy

Hergen Spits, University of Amsterdam, Netherlands
Harnessing the Power of the Immune System for Therapy: Past Present and Future

Daniel J. Cua, Merck Research Laboratories, USA
Autoimmunity

Short Talk Chosen from Abstracts

18:45–19:00 **Meeting Wrap-Up: Outcomes and Future Directions (Organizers)** [Colorado Ballroom](#)

[Registered attendees](#) can view abstracts starting on 01/18/2019

19:00–20:00 **Social Hour with Lite Bites** [Breckenridge Ballroom](#)
 No registration fees are used to fund alcohol served at this function.

20:00–23:00 **Entertainment** [Breckenridge Ballroom](#)

Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

SATURDAY, FEBRUARY 23

Departure

*Session Chair †Invited, not yet responded.

Keystone Symposia thanks our Sponsors for generously supporting this meeting:

The logo for Abbvie, featuring the word "abbvie" in a lowercase, sans-serif font.The logo for BioLegend, featuring a stylized figure with arms raised in a purple and yellow color scheme, followed by the word "BioLegend" in a purple serif font with a registered trademark symbol.The logo for Cancer Research UK, featuring a circular arrangement of colorful dots in shades of blue, purple, and pink, followed by the text "CANCER RESEARCH UK" in a blue sans-serif font.The logo for EMD Serono, featuring the words "EMD" and "SERONO" stacked vertically in a bold, blue, sans-serif font.The logo for Genentech, featuring the word "Genentech" in a bold, blue, sans-serif font, with the tagline "A Member of the Roche Group" in a smaller, italicized font below it.The logo for Incyte, featuring the word "Incyte" in a blue serif font, enclosed within a circular graphic composed of two overlapping arcs in purple and green.The logo for MacroGenics, featuring a stylized checkmark and a circular arc in grey, followed by the word "MACROGENICS" in a bold, orange, sans-serif font.The logo for MSD, featuring a green and white circular emblem, followed by the text "MSD" in a bold, black, sans-serif font, and the tagline "INVENTING FOR LIFE" in a smaller font below it.The logo for Morphosys, featuring the word "morphosys" in a bold, blue, sans-serif font, with the "m" and "p" characters stylized with vertical bars.The logo for OncoMed Pharmaceuticals, featuring a stylized "O" in a blue and gold color scheme, followed by the text "OncoMed" in a blue serif font and "PHARMACEUTICALS" in a smaller, all-caps sans-serif font below it.The logo for Pfizer, featuring the word "Pfizer" in a white, italicized, sans-serif font, set against a blue oval background.The logo for Roche, featuring the word "Roche" in a blue, sans-serif font, enclosed within a blue hexagonal border.



We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

[Click here to view more of these organizations](#)

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

[Click here to view more of these organizations](#)

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: **Sarah Lavicka**, Director of Development, Email: sarahl@keystonesymposia.org, Phone: +1 970-262-2690

[Click here](#) for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact: **Yvonne Psaila**, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone: +1 970-262-2676